Lugano, Switzerland, 23 February 2021 – The ESMO Targeted Anticancer Therapies Congress 2021, designed for basic scientists, physicians and translational researchers belonging to academic settings, industry and regulatory agencies will be held as a virtual meeting.
The scientific programme will provide new data and insightful presentations in the area of drug discovery and development for a broad range of targets, precision medicine and early clinical trial methodology. World renowned experts will discuss breakthroughs in the microbiome, oncolytic viruses and how to incorporate genomics into early drug development.
- Immune based therapies including ADCs, cytokines, multitargeted agents and cell-based therapies
- Oncolytic viruses
- The microbiome as a tool and a target
- Pre-clinical testing to identify effective combination strategies
- Incorporating genomics into early drug development
- Practical aspects of optimising molecular tumour boards for phase I trials
TAT2021 Honorary Award
Prof. Ruth Plummer will be presented with the TAT 2021 Honorary Award for taking many new cancer drugs into the clinic that have become standard treatments with proven patient benefit. She will deliver a keynote lecture entitled “Academic drug discovery – Is partnership with industry a marriage made in heaven?” (Monday 1 March, from 11:40 to 12:45).
During the same session Dr. Lillian Siu, recipient of the TAT 2020 Honorary Award for her pivotal contributions in the development of new anticancer drugs, will also deliver her keynote lecture entitled “Rear view mirror and crystal ball of oncology drug development”.
ESMO welcomes media interested in reporting from the ESMO events and on cancer issues. Only through the official accreditation process with the ESMO Media Registration Form, accredited media representatives will be able to access scientific and educational sessions (live streamed and on-demand), live chat and Q&A, e-posters, virtual exhibition and industry satellite symposia, Congress webcasts.
ESMO Press Office